Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending May 27, 2018
FDA postmarketing requirements, Nabhan C et al. JAMA Oncol. 2018 May 10. doi:10.1001/jamaoncol.2018.0610.
Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.
Dapagliflozin suppresses hepcidin, Ghanim HA et al. AACE 2018, Abstract 228.
Methotrexate or nelarabine plus chemo in pediatric T-ALL or T-L, Dunsmore KP et al. ASCO 2018, Abstract 10500.
Blood type is diarrhea destiny, Kumar P et al. J Clin Invest. 2018 May 17; doi: 10.1172/JCI97659.
Must reads for theWeek ending May 20, 2018
Widespread Zika screens not cost effective, Saá P et al. New Engl J Med. 2018;378:1778-88. doi: 10.1056/NEJMoa1714977
New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.
Good ALL outcomes in Down syndrome children, Maloney K et al. ASPHO 2018, annual meeting of the American Society of Pediatric Hematology/Oncology Abstract PP 2001
Reducing morbidity in postpartum hemorrhage, Smith R et al. Annual clinical and scientific meeting of the American Society of Obstetricians and Gynecologists 2018, Abstract 26R.
In sickle cell, start hydroxyurea in infancy, Schuchard S et al. ASPHO 2018, poster # 342 Schuchard S et al. ASPHO 2018, poster # 342. https://onlinelibrary.wiley.com/doi/10.1002/pbc.27057
Must reads for theWeek ending May 13, 2018
Fertility poor irrespective of conditioning regimen for transplants , Oquendo del Toro H et al. The 2018 Bone Marrow Transplant Tandem Meetings, Abstract 88.
Increase kidney function monitoring if INR exceeds 4.0, Traquair H et al. biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 79.
Comorbidity index reflects nonrelapse mortality for youths undergoing transplants, Friend B et al. ALF 2018, Poster Session.
Vaccination lags in children with sickle cell disease, Wagner AL et al. J Pediatr. 2018 May;196:223-9.
Relapse triggers high rate of haploidentical donor graft failure, Yanir AD et al. Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2018.03.001.
Must reads for theWeek ending April 22, 2018
Atovaquone associated with increased nocardiosis risk, Molina A et al. Acute Leukemia Forum 2018, Poster Session.
Add-on ibrutinib boosted response in relapsed multiple myeloma, Chari A et al. Leuk Lymphoma. 2018 Apr 4. doi: 10.1080/10428194.2018.1443337.
Adding statin boosted AML response rate, Advani AS et al. Leuk Res. 2018 Apr;67:17-20.
Venetoclax is effective in CLL that relapses after idelalisib, , Coutre S et al. Blood. 2018;131(15):1704-11
Pembrolizumab after cytarabine boosts AML response, Zeidner J et al. Acute Leukemia Forum 2018, Poster Session.
Must reads for theWeek ending January 7, 2018
Algorithm Predicts Matched Unrelated Donor Odds, Biol Blood Marrow Transplant; ePub 2017 Dec 26; Davis, et al
Chemo-Alone vs Combo Regimens in Advanced NHL , Clin Lymphoma Myeloma Leuk; ePub 2017 Dec 29; Song, et al
Value of Revaccinating People with MM After aHCT , Biol Blood Marrow Transplant; ePub 2017 Dec 27; Palazzo, et al
Outcomes in Older Transplant Patients with AML/MDS , Biol Blood Marrow Transplant; ePub 2017 Dec 27; Tsai, et al
Triggers of Hypercalcemia in Patients with NHL, Clin Lymphoma Myeloma Leuk; ePub 2017 Dec 29; Shallis, et al
